Author

K. Owusu-Edusei

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18-64 years in Switzerland using PCV21.

BACKGROUND Pneumococcal disease (PD) is more common and severe among adults with underlying medical conditions. Pneumococcal vaccination is recommended but not reimbursed in Switzerland for adults 18-64 years with these risk factors. OBJECTIVE We estimated the cost-effectiveness of reimbursed vaccination for high-ris...

Muloongo Simuzingili, Z. Yi, A. Favre-Bulle et al. · Journal of Medical Economics · 0 citations

Aug 2026

Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged ≥45 years in Spain.

INTRODUCTION PCV21, a 21-valent pneumococcal conjugate vaccine (PCV), includes eight unique serotypes not covered by other currently licensed pneumococcal vaccines, and accounts for approximately 79% of IPD cases among adults aged ≥65 years in Spain, compared with 65% for PCV20. This study evaluated the potential lifet...

M. Simuzingili, Silvia Fernández-Soberón, Z. Yi et al. · Vaccine · 0 citations

Open access Aug 2026

The health and economic burden of invasive pneumococcal diseases attributable to PCV21 versus PCV20 serotypes among adults aged ≥ 45 years in Spain

The serotypes targeted by PCV21 impose a significantly higher health and economic burden of IPD in Spain relative to PCV20, and may help reduce the health and economic burden of IPD among Spanish adults, supporting its incorporation into national vaccination guidelines and adult immunization strategies.

M. Simuzingili, Silvia Fernández-Soberón, Z. Yi et al. · BMC Public Health · 0 citations